SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Cardarine / GW501516	SR9009	AICAR (Acadesine)
Research Topic	Clinical / Endocrine Pharmacology	Mitochondrial / Metabolic Research	Mitochondrial / Metabolic Research
Pharmacology	Experimental PPAR-beta/delta agonist; not a SARM	Experimental small molecule / REV-ERB-related research	Investigational purine nucleoside analogue / adenosine-regulating agent; not a peptide
PrimeCore Class	Class BInvestigational	Class CExperimental / limited evidence	Class BInvestigational
Evidence Grade	Grade BStrong controlled human evidence	Grade EPreclinical evidence	Grade BStrong controlled human evidence
Evidence boundary	Cardarine, GW501516 and GW1516 identify an experimental PPAR-beta/delta agonist, not a SARM or anabolic steroid. Short controlled human studies reported lipid-biomarker changes but did not establish cardiovascular-event reduction, fat loss, endurance benefit or long-term safety. Animal studies report tumour-promoting signals in susceptible models; these do not quantify human incidence but preclude a proven-safety claim. WADA 2026 prohibits GW501516 at all times as a metabolic modulator.	SR9009 is an experimental small molecule, not a SARM or peptide. Genetic studies demonstrate REV-ERB-independent effects, limiting target-specific claims. Cell and mouse results do not establish human fat-loss, endurance or cardiac benefit, and human safety remains unverified.	A nucleoside analogue and AMPK-related research compound, not a peptide; clinical and anti-doping contexts must be separated.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	long-term safety outside short perioperative research settings human risk-benefit for weight, metabolic or performance claims effects of repeated exposure on purine, glucose and lipid metabolism comparability of research-grade AICAR, acadesine formulations and online products current product-specific marketing-authorisation status in Thailand, the EU and UK current US compounding-list status under a substance-specific FDA review
Limitations	PPAR-delta agonist ≠ SARM; lipid biomarker change ≠ cardiovascular benefit; mouse tumour signal ≠ quantified human incidence but cannot be dismissed as proof of safety	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) SR9009 ≠ SARM; mouse metabolism ≠ human exercise benefit; เป้าหมายที่คาดไม่เท่ากับกลไกที่พิสูจน์ครบ	Strong controlled human evidence exists only in a narrow CABG setting and culminated in a negative confirmatory trial. Older meta-analytic and post-hoc signals must be interpreted in light of RED-CABG. Popular performance claims are based mainly on mouse work. Mechanistic studies also show that AICAR is not selective for AMPK, limiting simple pathway-based conclusions.
Sources	First human metabolic study · PMID 17110604 Internet products marketed as SARMs · PMID 29183075 WADA · 2026 Prohibited List Low-HDL metabolic study · PMID 22814748 PPAR-delta mammary-neoplasia model · PMID 23811944	Target-specificity study · PMID 31127047 Cardiac knockout model · PMID 35911512	https://precision.fda.gov/uniisearch/srs/unii/53ief47846 https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=203105 https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=341011 https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://clinicaltrials.gov/study/NCT00872001 https://pubmed.ncbi.nlm.nih.gov/7818622/ https://pubmed.ncbi.nlm.nih.gov/7574044/ https://pubmed.ncbi.nlm.nih.gov/9002496/ https://pubmed.ncbi.nlm.nih.gov/22782417/ https://pubmed.ncbi.nlm.nih.gov/7744080/ https://pubmed.ncbi.nlm.nih.gov/18674809/ https://pubmed.ncbi.nlm.nih.gov/27103440/ https://pubmed.ncbi.nlm.nih.gov/34064363/ https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://products.mhra.gov.uk/ https://www.ema.europa.eu/en/medicines/download-medicine-data https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.